Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Q2 Vaccine Sales Top $1 Billion On Strength Of New Products

Executive Summary

Sales of Merck's vaccines, including the human papillomavirus vaccine Gardasil, the rotavirus vaccine Rotateq and the herpes zoster vaccine Zostavax, reached more than $1 billion, reflecting a 199 percent increase over the second quarter of 2006, the company reported July 23
Advertisement

Related Content

Gardasil’s Strong Launch May Be Suppressing Merck’s M&A Appetite
Gardasil’s Strong Launch May Be Suppressing Merck’s M&A Appetite
Merck Faces Varicella-Zoster Virus Supply Shortage For Vaccine Production
Merck’s Licensing Philosophy Mixes Acquisitions And Development Deals
Advertisement
UsernamePublicRestriction

Register

PS048626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel